^
Association details:
| Biomarker: | CD20 expression + TNFRSF8 overexpression |
|---|---|
| Cancer: | Lymphoma |
| Regimen: | (doxorubicin hydrochloride + Adcetris (brentuximab vedotin) + cyclophosphamide + Rituxan (rituximab) + prednisone) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy
Excerpt:
We present a case of a patient initially diagnosed with cHL who underwent repeat biopsy which was revealed to be GZL. Based on PET scanning and immunohistochemical studies, she was classified as a stage IIIA CD20+/CD30+ GZL patient. Given her strong CD30 expression, she underwent 6 cycles of R-BV-CHP (rituximab, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone) chemotherapy and achieved complete response (CR) both clinically and radiographically.
DOI:
10.1155/2019/4121234
